By Josh Beckerman
Syros Pharmaceuticals said it plans to wind down its operations, according to a Securities and Exchange Commission filing.
The Cambridge, Mass., company said it would proceed with a voluntary delisting from Nasdaq.
Syros shares last traded at 14 cents, down 0.8%. The stock was halted due to pending news.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
By Josh Beckerman
Syros Pharmaceuticals, which said in November it would cut most of its workforce, said on Friday it will wind down operations.
The company's stock dropped 45% to 8 cents in after-hours trading. Through the market's close shares have plunged 98% in the last year.
Syros is voluntarily delisting its stock from Nasdaq.
The company said in November that it planned to reduce its workforce by about 94% after a Phase 3 study of tamibarotene failed to meet its primary endpoint.
The failure constituted an event of default under its secured loan facility with Oxford Finance LLC. Syros said that it agreed to operate its business as a wind-down and limit its expenditures in accordance with a budget approved by Oxford.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 28, 2025 17:27 ET (22:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.